Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study-Reference-Cited by-同舟云学术

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Published:2016-11 Issue:11 Volume:17 Page:1497-1508
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Langer Corey J,Gadgeel Shirish M,Borghaei Hossein,Papadimitrakopoulou Vassiliki A,Patnaik Amita,Powell Steven F,Gentzler Ryan D,Martins Renato G,Stevenson James P,Jalal Shadia I,Panwalkar Amit,Yang James Chih-Hsin,Gubens Matthew,Sequist Lecia V,Awad Mark M,Fiore Joseph,Ge Yang,Raftopoulos Harry,Gandhi Leena

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

2. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL);Reck;Ann Oncol,2010

3. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon;N Engl J Med,2015

4. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer;Chatterjee;Ann Oncol,2016

5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

Cited by 1218 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Road Ahead in Pancreatic Cancer: Emerging Trends and Therapeutic Prospects;Biomedicines;2024-09-02

2. Cobalt(III) prodrug-based nanomedicine for inducing immunogenic cell death and enhancing chemo-immunotherapy;Journal of Controlled Release;2024-09

3. Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial;The Lancet Respiratory Medicine;2024-09

4. Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer;Cochrane Database of Systematic Reviews;2024-08-13

5. Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis;The Lancet Oncology;2024-08